Antibody Drug Conjugates Market: Global Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2016 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Global Antibody Drug Conjugates Market By Product Type (Kadcyla, Adcertis, Others), By Application (Leukemia, Lymphoma), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Antibody Drug Conjugates Market size is valued at USD 4.84 billion in 2021 and is expected to reach USD 9.87 billion by 2028, at a CAGR of 12.6% during the forecast period 2022-2028. ADCs are a type of biopharmaceutical used to treat cancer that consists of an antibody that selectively targets a tumour antigen and a cytotoxic agent linked together by a chemical linker. ADCs are designed to allow the cytotoxic substance to be targeted specifically to kill cancer cells while having a minimal effect on healthy tissue. Antibody drug conjugates are made up of three parts: an antibody specific for the target associated antigen, an antigen that has limited expression on normal cells, a cytotoxic agent that kills target cancer cells, and a chemical linker that connects the cytotoxic agent to the antibody. Antibody drug conjugates have therapeutic potential but face technological and developmental obstacles. Antibody drug conjugates are thought to be the next generation of therapeutics. They combine the ability of monoclonal antibodies to target specific cells with the ability of cytotoxic medicines to kill those cells. Only with rising technological developments has this technology been able to succeed. Antibody drug conjugates are a new therapeutic class that is attracting the attention of both large and small pharmaceutical businesses. this report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, The global Antibody Drug Conjugates Market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global Market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).

Antibody Drug Conjugates Market

MARKET SUMMARY
-
12.6%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 12.6%
  • Largest Market– North-America
  • Fastest Growing Market– Europe

Antibody Drug Conjugates Market

  • The global Antibody Drug Conjugates Market report gives comprehensive outlook on Antibody Drug Conjugates Market across the globe with special emphasis on key regions such as Asia Pacific, North America, Europe, Latin America, and Middle East and Africa.
  • The report on global Antibody Drug Conjugates Market gives historical, current, and future market sizes (US$ Mn) on the basis of type, end-user and Region.
  • In September 2017, Pfizer, Inc. received FDA approval for the Mylotarg (Gemtuzumab Ozogamicin), and antibody drug conjugate used in newly diagnosed and relapsed or refractory CD33-Positive acute myeloid leukemia.
key players
  • Roche Holding AG (Switzerland)
  • Pfizer Inc. (U.S.)
  • Bayer HealthCare (Germany)
  • Progenics Pharmaceuticals (U.S.)
  • Roche Holding AG (Switzerland)
Antibody Drug Conjugates Market

DRIVERS AND RESTRAINTS

The advancement of medical technology is projected to fuel the global market for antibody drug conjugates. The market’s main drivers include an increase in cancer incidence, a growing elderly population, and an increase in obese people.


North-America got significant share

Antibody Drug Conjugates Market

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

Antibody Drug Conjugates Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content

  1. 1. Executive Summary
    2. Global Antibody Drug Conjugate Market Introduction
    2.1. Global Antibody Drug Conjugate Market – Taxonomy
    2.2. Global Antibody Drug Conjugate Market –Definitions
    2.2.1. By Drugs
    2.2.2. By Mechanism Of Action
    2.2.3. By Application
    2.2.4. By Region
    3. Global Antibody Drug Conjugate Market Dynamics
    3.1. Drivers
    3.2. Restraints
    3.3. Opportunities/Unmet Needs of the Market
    3.4. Trends
    3.5. Global Antibody Drug Conjugate Market Dynamic Factors – Impact Analysis
    3.6. Global Antibody Drug Conjugate Market – Competition Landscape
    4. Global Antibody Drug Conjugate Market Analysis, 2017-2021 and Forecast, 2022-2028
    4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
    4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
    4.3. Market Opportunity Analysis
    5. Global Antibody Drug Conjugate Market, By Drugs, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) 
    5.1. Adcetris
    5.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
    5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    5.1.3. Market Opportunity Analysis
    5.2. Kadcyla
    5.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
    5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    5.2.3. Market Opportunity Analysis
    6. Global Antibody Drug Conjugate Market, By Mechanism of Action, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) 
    6.1. CD30 Antibodies
    6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
    6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    6.1.3. Market Opportunity Analysis
    6.2. HER2 Antibodies
    6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
    6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    6.2.3. Market Opportunity Analysis
    7. Global Antibody Drug Conjugate Market Forecast, By Application, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) 
    7.1. Breast Cancer
    7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
    7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    7.1.3. Market Opportunity Analysis
    7.2. Lymphoma
    7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
    7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    7.2.3. Market Opportunity Analysis
    8. Global Antibody Drug Conjugate Market Forecast, By Region, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) 
    8.1. North America
    8.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
    8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    8.1.3. Market Opportunity Analysis
    8.2. Europe
    8.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
    8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    8.2.3. Market Opportunity Analysis
    8.3. Asia-Pacific
    8.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
    8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    8.3.3. Market Opportunity Analysis
    8.4. Latin America
    8.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
    8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    8.4.3. Market Opportunity Analysis
    8.5. Middle East and Africa
    8.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
    8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    8.5.3. Market Opportunity Analysis
    8.6. Global Antibody Drug Conjugate Market – Opportunity Analysis Index, By Drugs, By Mechanism Of Action, By Application and Region, 2022-2028
    9. North America Antibody Drug Conjugate Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) 
    9.1. Drugs Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    9.1.1. Adcetris
    9.1.2. Kadcyla
    9.2. Mechanism Of Action Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    9.2.1. CD30 Antibodies
    9.2.2. HER2 Antibodies
    9.3. Application Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    9.3.1. Breast Cancer
    9.3.2. Lymphoma
    9.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    9.4.1. USA
    9.4.2. Canada
    9.5. North America Antibody Drug Conjugate Market – Opportunity Analysis Index, By Drugs, By Mechanism of Action, By Application, and Country, 2022-2028
    9.6. North America Antibody Drug Conjugate Market Dynamics – Trends
    10. Europe Antibody Drug Conjugate Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) 
    10.1. Drugs Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.1.1. Adcetris
    10.1.2. Kadcyla
    10.2. Mechanism Of Action Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.2.1. CD30 Antibodies
    10.2.2. HER2 Antibodies
    10.3. Application Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.3.1. Breast Cancer
    10.3.2. Lymphoma
    10.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    10.4.1. Germany
    10.4.2. UK
    10.4.3. France
    10.4.4. Spain
    10.4.5. Italy
    10.4.6. Russia
    10.4.7. Rest of Europe
    10.5. Europe Antibody Drug Conjugate Market – Opportunity Analysis Index, By Drugs, By Mechanism of Action, By Application, and Country, 2022-2028
    10.6. Europe Antibody Drug Conjugate Market Dynamics – Trends
    11. Asia-Pacific Antibody Drug Conjugate Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) 
    11.1. Drugs Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    11.1.1. Adcetris
    11.1.2. Kadcyla
    11.2. Mechanism Of Action Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    11.2.1. CD30 Antibodies
    11.2.2. HER2 Antibodies
    11.3. Application Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    11.3.1. Breast Cancer
    11.3.2. Lymphoma
    11.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    11.4.1. China
    11.4.2. India
    11.4.3. Japan
    11.4.4. ASEAN
    11.4.5. Australia & New Zealand
    11.4.6. Rest of Asia-Pacific
    11.5. Asia-Pacific Antibody Drug Conjugate Market – Opportunity Analysis Index, By Drugs, By Mechanism of Action, By Application and Country, 2022-2028
    11.6. Asia-Pacific Antibody Drug Conjugate Market Dynamics – Trends
    12. Latin America Antibody Drug Conjugate Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) 
    12.1. Drugs Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.1. Adcetris
    12.1.2. Kadcyla
    12.2. Mechanism Of Action Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.2.1. CD30 Antibodies
    12.2.2. HER2 Antibodies
    12.3. Application Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.3.1. Breast Cancer
    12.3.2. Lymphoma
    12.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    12.4.1. Brazil
    12.4.2. Mexico
    12.4.3. Argentina
    12.4.4. Rest of Latin America
    12.5. Latin America Antibody Drug Conjugate Market – Opportunity Analysis Index, By Drugs, By Mechanism of Action, By Application and Country, 2022-2028
    12.6. Latin America Antibody Drug Conjugate Market Dynamics – Trends
    13. Middle East and Africa Antibody Drug Conjugate Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) 
    13.1. Drugs Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.1. Adcetris
    13.1.2. Kadcyla
    13.2. Mechanism Of Action Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.2.1. CD30 Antibodies
    13.2.2. HER2 Antibodies
    13.3. Application Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.3.1. Breast Cancer
    13.3.2. Lymphoma
    13.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    13.4.1. Gulf Cooperation Council (GCC) Countries
    13.4.2. Israel
    13.4.3. South Africa
    13.4.4. Rest of MEA
    13.5. MEA Antibody Drug Conjugate Market – Opportunity Analysis Index, By Drugs, By Mechanism of Action, By Application and Country, 2022-2028
    13.6. MEA Antibody Drug Conjugate Market Dynamics – Trends
    14. Competition Landscape 
    14.1. Strategic Dashboard of Top Market Players
    14.2. Company Profiles (Introduction, Financial Analysis, Drugss, Key Developments, Strategies, and SWOT Analysis)
    14.2.1. F. Hoffman-La Roche Ltd.
    14.2.2. Novartis AG
    14.2.3. Takeda Pharmaceutical Company Limited
    14.2.4. Pfizer, Inc.
    14.2.5. Amar Chemistry
    14.2.6. Seattle Genetics Inc.
    14.2.7. Genentech Inc.
    14.2.8. Immunogen Inc.
    14.2.9. Immunomedics, Inc.
    14.2.10. Progenics Pharmaceuticals Inc.
    14.2.11. Bayer Healthcare Pharmaceuticals
    15. Research Methodology
    16. Key Assumptions and Acronyms

Report

Company Profile

  • Roche Holding AG (Switzerland)
  • Pfizer Inc. (U.S.)
  • Bayer HealthCare (Germany)
  • Progenics Pharmaceuticals (U.S.)
  • Roche Holding AG (Switzerland)
  • ImmunoGen, Inc. (U.S.)
  • Celldex Therapeutics (U.S.)
  • AbbVie Inc. (U.S.)
  • Millennium Pharmaceuticals (U.S.)
  • Agensys, Inc. (U.S.)

Report

Ask An Analyst

 

Description

Antibody Drug Conjugates Market size is valued at USD 4.84 billion in 2021 and is expected to reach USD 9.87 billion by 2028, at a CAGR of 12.6% during the forecast period 2022-2028. ADCs are a type of biopharmaceutical used to treat cancer that consists of an antibody that selectively targets a tumour antigen and a cytotoxic agent linked together by a chemical linker. ADCs are designed to allow the cytotoxic substance to be targeted specifically to kill cancer cells while having a minimal effect on healthy tissue. Antibody drug conjugates are made up of three parts: an antibody specific for the target associated antigen, an antigen that has limited expression on normal cells, a cytotoxic agent that kills target cancer cells, and a chemical linker that connects the cytotoxic agent to the antibody. Antibody drug conjugates have therapeutic potential but face technological and developmental obstacles. Antibody drug conjugates are thought to be the next generation of therapeutics. They combine the ability of monoclonal antibodies to target specific cells with the ability of cytotoxic medicines to kill those cells. Only with rising technological developments has this technology been able to succeed. Antibody drug conjugates are a new therapeutic class that is attracting the attention of both large and small pharmaceutical businesses. this report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, The global Antibody Drug Conjugates Market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global Market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX